European regulators cleared Moderna’s first-of-its-kind vaccine as US approval remains uncertain. On Friday, Moderna’s ...

COMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending ...

COMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents Moderna's fourth vaccine to receive a positive C ...

The February 2026 meeting of the EMA's Committee for Medicinal Products for Human Use (CHMP) resulted in recommendations for twelve new medicines.¹ These outcomes, which included recommendations for ...

Since the 1990s, the FDA has collected fees from drug companies to help pay for extra staffers to quickly review new ...

When outcome selection and prioritisation are defined early in development, the evidence base supports continuity from trial ...

Enteromix journey began with a Phase I clinical trial conducted between June and December 2025, involving just 48 volunteers ...

Moderna, Inc. (NASDAQ: MRNA) shares are swinging in volatile early trading on Friday, February 27, 2026, as investors digest ...

The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be ...

With the CHMP affirmation, Moderna is on course to get EU approval for its fourth vaccine product and break new ground in ...

Feb 27 (Reuters) - Europe's medicines regulator on Friday recommended approval for Moderna's mCombriax, paving the way for it to become the first combined shot for protecting people aged 50 and older ...

In issuing a positive recommendation, the EMA has diverged from the FDA, which has set higher approval standards for ...